Norden Group LLC Has $744,000 Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Norden Group LLC increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 11.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,848 shares of the pharmaceutical company’s stock after acquiring an additional 183 shares during the quarter. Norden Group LLC’s holdings in Vertex Pharmaceuticals were worth $744,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Dunhill Financial LLC lifted its stake in Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 24 shares during the period. Brown Lisle Cummings Inc. bought a new position in shares of Vertex Pharmaceuticals during the fourth quarter worth about $30,000. Legacy Investment Solutions LLC acquired a new position in Vertex Pharmaceuticals during the third quarter valued at approximately $33,000. Truvestments Capital LLC acquired a new position in Vertex Pharmaceuticals during the third quarter valued at approximately $35,000. Finally, Sugar Maple Asset Management LLC acquired a new position in Vertex Pharmaceuticals during the fourth quarter valued at approximately $35,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

Shares of Vertex Pharmaceuticals stock opened at $483.31 on Tuesday. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The firm has a market capitalization of $124.11 billion, a price-to-earnings ratio of -219.69, a PEG ratio of 2.11 and a beta of 0.41. The business has a 50-day simple moving average of $441.95 and a 200 day simple moving average of $461.06. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. On average, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on VRTX. UBS Group raised their price objective on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Bank of America cut their price objective on Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a research report on Thursday, December 19th. William Blair reaffirmed an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. Canaccord Genuity Group raised Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and lifted their price target for the stock from $408.00 to $424.00 in a report on Tuesday, February 11th. Finally, Stifel Nicolaus lifted their price target on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a report on Monday, December 16th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $506.70.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 244 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total transaction of $111,034.64. Following the completion of the sale, the executive vice president now directly owns 67,695 shares of the company’s stock, valued at approximately $30,805,286.70. The trade was a 0.36 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders sold 1,084 shares of company stock valued at $505,512. Corporate insiders own 0.20% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.